• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Offers Advice on Standardizing Real-World Data for IND Submissions

FDA Offers Advice on Standardizing Real-World Data for IND Submissions

October 25, 2021

The FDA has acknowledged the challenges sponsors face in standardizing study data taken from real-world data (RWD) sources and issued draft guidance to help sponsors make adjustments.

These hurdles include the variety of RWD sources and their inconsistent formats; the differences in source data obtained regionally and globally using different standards, exchange formats and terminologies to represent the same or similar data elements; the variety of methods and algorithms used to make datasets meant to aggregate data; and the many elements of healthcare data that can impact overall data quality.

Sponsors are required to use the data formats and standards outlined in the agency’s Study Data Guidance and Data Standards Catalog when submitting study data derived from RWD in investigational new drug (IND) applications.

Because of this, the agency advises sponsors to refer to the Study Data Technical Conformance Guide, which outlines how to submit standardized study data that meet agency expectations.

In addition, when conforming RWD to agency-supported data standards, sponsors should consider the data transformations, conversions or mappings that may be needed to produce adequate study datasets. To aid them in this, the guidance provides sponsors with considerations to make when mapping and transforming RWD.

Importantly, sponsors are encouraged to communicate with the FDA early on if they plan to include study data taken from RWD sources in an applicable submission. If so, they should describe the approaches they intend to use to convert the data to supported data standards in the protocol, data management plan and/or final study reports.

The FDA said it intends to release further guidance on the subject and/or update the catalog with standards for study data taken from RWD sources.

Read the full guidance here: https://bit.ly/3C3LXQF.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 27Jul

    Applying the Lessons of the Pandemic to Your Upcoming Trial

  • 16Oct

    WCG MAGI's Clinical Research Conference 2022 West

  • 16Nov

    17th Annual FDA Inspections Summit

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Strategy-360x240.png

    Site Spotlight: Less Is More in Adams Clinical’s Research Strategy

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Efficient and Effective Coverage Analysis

  • InclusionRed-360x240.png

    Inclusion Gaps Linger for Trans and Nonbinary Populations, Special Accommodations Needed

  • CostsBenefits-360-240.png

    Decentralized Methods Gain Far More Than They Cost, New Data Show

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing